Drug-drug Interaction Study With AZD5335 and Itraconazole in Participants With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Time to maximum observed concentration (tmax)

tmax of AZ14170132 will be assessed.

Time frame: Cycle 2 and Cycle 3 (each cycle is of 21 days)

Number of participants with adverse events (AEs) and serious adverse events (SAEs)

The safety and tolerability of AZD5335 alone and in combination with itraconazole will be assessed.

Time frame: Part A: up to 121 days; Part B: up to 365 days post last participant first dose

Objective response rate (ORR)

The ORR is defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR), with the denominator defined as the number of participants in the response evaluable set.

Time frame: Part A: up to 121 days; Part B: up to 365 days post last participant first dose

Duration of response (DoR)

The DoR is defined as the time from the date of first documented objective response (which is subsequently confirmed) until date of first documented disease progression or death (by any cause in the absence of disease progression).

Time frame: Part A: up to 121 days; Part B: up to 365 days post last participant first dose

Progression-free Survival (PFS)

The PFS is defined as the time from the start of treatment until the date of objective disease progression or death (by any cause in the absence of progression), regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy prior to progression.

Time frame: From Day 1 until until disease progression or death (up to 2 years)